Pegfilgrastim

• CAS Number: 208265-92-3

Pegfilgrastim is a recombinant human pegylated granulocyte colony stimulating factor (G -CSF), which stimulates the formation of leukocytes. PEGylation by pegfilgrastim has a longer half-life of 15 to 80 h as the unpegylierte filgrastim (approx. 3.5 h).

Clinical information

Pegfilgrastim is often used in chemotherapy-induced leukopenia and injected subcutaneously.

Side effects (NW) bone pain, headache, flu-like symptoms and fever can occur (see also NW of G -CSF).

Rights

2002 Roche ceded his rights to filgrastim and pegfilgrastim as well as the relevant assets for the area of the European Union, Switzerland and Norway to the U.S. firm Amgen for $ 137.5 million. This, after the Japanese subsidiary of Roche announced a merger with the Japanese Chugai Pharmaceutical Co.. Chugai markets with lenograstim a competing product.

Trade names

Neulasta (D, CH), Neupopeg (A)